• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.

作者信息

Cubero Daniel I G, Del Giglio Auro

机构信息

Department of Oncology and Haematology, ABC Foundation School of Medicine, Av. Principe de Gales, n.821, anexo 3, Santo André/SP, 09060-650, Brazil.

出版信息

Ther Adv Med Oncol. 2013 Jan;5(1):93-4. doi: 10.1177/1758834012469430.

DOI:10.1177/1758834012469430
PMID:23323151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3539279/
Abstract
摘要

相似文献

1
Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.低剂量替加氟-尿嘧啶（UFT）对部分二氢嘧啶脱氢酶缺乏的结直肠癌患者治疗是安全的：一项原理验证。
Ther Adv Med Oncol. 2013 Jan;5(1):93-4. doi: 10.1177/1758834012469430.
2
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.替加氟-尿嘧啶是治疗部分二氢嘧啶脱氢酶缺乏的结直肠癌患者的安全替代药物：原理验证。
Ther Adv Med Oncol. 2012 Jul;4(4):167-72. doi: 10.1177/1758834012441049.
3
Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.二氢嘧啶脱氢酶在肿瘤组织中的表达对Ⅰ期非小细胞肺癌患者术后给予优福定（替加氟+尿嘧啶）疗效的预测价值。
J Surg Oncol. 2002 Oct;81(2):87-92. doi: 10.1002/jso.10137.
4
Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.口服尿嘧啶和替加氟长期辅助治疗结直肠癌期间的二氢嘧啶脱氢酶活性
Chemotherapy. 2007;53(6):442-5. doi: 10.1159/000110016. Epub 2007 Oct 22.
5
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.5-乙炔基尿嘧啶（776C85）：对5-氟尿嘧啶前体药物替加氟的抗肿瘤活性和药代动力学的影响。
Cancer Res. 1995 Dec 15;55(24):6227-30.
6
UFT in the treatment of colorectal and breast cancer.优福定治疗结直肠癌和乳腺癌。
Oncology (Williston Park). 2001 Jan;15(1 Suppl 2):49-56.
7
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.标准剂量替加氟-尿嘧啶（UFT）对于部分二氢嘧啶脱氢酶缺乏的患者而言并非安全的替代药物。
Ther Adv Med Oncol. 2013 Jan;5(1):91-2. doi: 10.1177/1758834012464806.
8
Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer.术前放疗联合卡培他滨（UFT）和亚叶酸治疗局部进展期直肠癌的 II 期研究。
BMC Cancer. 2011 Mar 16;11:98. doi: 10.1186/1471-2407-11-98.
9
Uracil-tegafur in gastric carcinoma: a comprehensive review.尿嘧啶替加氟在胃癌中的应用：综述
J Clin Oncol. 1998 Aug;16(8):2877-85. doi: 10.1200/JCO.1998.16.8.2877.
10
Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.环磷酰胺通过抑制二氢嘧啶脱氢酶增强尿嘧啶和替加氟的抗肿瘤疗效。
Oncol Rep. 2007 Jan;17(1):153-9.

引用本文的文献

1
The Prognostic and Predictive Value of Dihydropyrimidine Dehydrogenase-Related Indicators in Clinical Outcomes of Chemotherapy in Colorectal Cancer Patients: a Systematic Review and Meta-Analysis.二氢嘧啶脱氢酶相关指标在结直肠癌患者化疗临床结局中的预后和预测价值：系统评价和荟萃分析。
Pathol Oncol Res. 2020 Jan;26(1):121-131. doi: 10.1007/s12253-018-00563-3. Epub 2018 Dec 5.
2
Germline oncopharmacogenetics, a promising field in cancer therapy.生殖系肿瘤药物遗传学，癌症治疗中一个有前景的领域。
Cell Oncol (Dordr). 2015 Feb;38(1):65-89. doi: 10.1007/s13402-014-0214-4. Epub 2015 Jan 9.

本文引用的文献

1
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.标准剂量替加氟-尿嘧啶（UFT）对于部分二氢嘧啶脱氢酶缺乏的患者而言并非安全的替代药物。
Ther Adv Med Oncol. 2013 Jan;5(1):91-2. doi: 10.1177/1758834012464806.
2
Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.替加氟-尿嘧啶是治疗部分二氢嘧啶脱氢酶缺乏的结直肠癌患者的安全替代药物：原理验证。
Ther Adv Med Oncol. 2012 Jul;4(4):167-72. doi: 10.1177/1758834012441049.
3
Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.在出现5-氟尿嘧啶或卡培他滨严重毒性反应后，标准剂量替加氟联合尿嘧啶并非安全的治疗方法。
Ann Intern Med. 2010 Dec 7;153(11):767-8. doi: 10.7326/0003-4819-153-11-201012070-00023.
4
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.与白种人相比，非裔美国人中二氢嘧啶脱氢酶缺乏症的患病率更高。
Clin Cancer Res. 2006 Sep 15;12(18):5491-5. doi: 10.1158/1078-0432.CCR-06-0747.
5
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.替加氟/尿嘧啶与口服亚叶酸钙对比肠外氟尿嘧啶与亚叶酸钙用于既往未治疗的转移性结直肠癌患者的随机对照研究。
J Clin Oncol. 2002 Sep 1;20(17):3617-27. doi: 10.1200/JCO.2002.10.129.
6
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.尿嘧啶/替加氟与口服亚叶酸钙对比氟尿嘧啶与亚叶酸钙用于既往未治疗的转移性结直肠癌患者的多中心III期研究。
J Clin Oncol. 2002 Sep 1;20(17):3605-16. doi: 10.1200/JCO.2002.04.123.
7
Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.乳腺癌患者群体中二氢嘧啶脱氢酶活性降低：对基于5-氟尿嘧啶化疗的影响。
Clin Cancer Res. 1998 Feb;4(2):325-9.
8
Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.人外周血单个核细胞和肝脏中的二氢嘧啶脱氢酶活性：群体特征、新发现的缺陷患者以及5-氟尿嘧啶化疗的临床意义
Cancer Res. 1993 Nov 15;53(22):5433-8.
9
Population study of dihydropyrimidine dehydrogenase in cancer patients.癌症患者中二氢嘧啶脱氢酶的群体研究。
J Clin Oncol. 1994 Nov;12(11):2248-53. doi: 10.1200/JCO.1994.12.11.2248.